NasdaqGS - Nasdaq Real Time Price USD

Cumberland Pharmaceuticals Inc. (CPIX)

5.71
+0.75
+(15.12%)
At close: June 2 at 4:00:02 PM EDT
5.67
-0.04
(-0.70%)
After hours: June 2 at 7:56:05 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
41,083.30
37,867.95
39,552.51
42,010.95
35,985.04
Cost of Revenue
6,436.14
6,585.97
6,066.61
9,118.52
8,811.25
Gross Profit
34,647.16
31,281.97
33,485.90
32,892.43
27,173.80
Operating Expense
37,918.37
37,714.38
43,040.56
38,597.36
34,851.22
Operating Income
-3,271.21
-6,432.41
-9,554.66
-5,704.93
-7,677.42
Net Non Operating Interest Income Expense
-287.38
-271.06
-381.01
-487.59
-71.95
Other Income Expense
--
237.09
3,650.67
611.33
2,187.14
Pretax Income
-3,321.50
-6,466.38
-6,285
-5,581.19
-5,562.23
Tax Provision
-28.44
-22.67
45.77
68.85
34.89
Net Income Common Stockholders
-3,276.44
-6,479.77
-6,279.32
-5,570.24
-3,507.59
Diluted NI Available to Com Stockholders
-3,276.44
-6,479.77
-6,279.32
-5,570.24
-3,507.59
Basic EPS
-0.24
-0.46
-0.44
-0.38
-0.24
Diluted EPS
-0.24
-0.46
-0.44
-0.38
-0.24
Basic Average Shares
14,271.40
14,060.27
14,298.77
14,563.59
14,904.83
Diluted Average Shares
14,350.72
14,060.27
14,298.77
14,563.59
14,904.83
Total Operating Income as Reported
-3,271.21
-6,432.41
-9,554.66
-5,704.93
-7,677.42
Total Expenses
44,354.51
44,300.35
49,107.17
47,715.88
43,662.46
Net Income from Continuing & Discontinued Operation
-3,276.44
-6,479.77
-6,279.32
-5,570.24
-3,507.59
Normalized Income
-3,511.50
-6,716.05
-6,928.54
-6,053.19
-5,501.91
Interest Income
363.41
334.44
286.85
98.41
26.08
Interest Expense
650.78
605.51
667.86
586
98.03
Net Interest Income
-287.38
-271.06
-381.01
-487.59
-71.95
EBIT
-2,670.72
-5,860.88
-5,617.14
-4,995.19
-5,464.20
EBITDA
3,253.48
182.42
2,485.51
332.92
-857.83
Reconciled Cost of Revenue
5,154.87
5,290.93
8,398.81
8,857.78
8,576.18
Reconciled Depreciation
5,924.20
6,043.30
5,770.45
5,328.11
4,606.37
Net Income from Continuing Operation Net Minority Interest
-3,276.44
-6,479.77
-6,279.32
-5,570.24
-5,501.91
Total Unusual Items Excluding Goodwill
237.09
237.09
821.80
611.33
0
Total Unusual Items
237.09
237.09
821.80
611.33
0
Normalized EBITDA
3,016.39
-54.67
1,663.71
-278.41
-857.83
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
2.03
0.81
172.58
128.38
0
12/31/2021 - 8/11/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LFCR Lifecore Biomedical, Inc.
6.87
+1.48%
 
ANIK Anika Therapeutics, Inc.
11.45
+2.69%
 
UTHR United Therapeutics Corporation
325.48
+2.08%
 
KMDA Kamada Ltd.
6.90
+0.73%
 
AMRX Amneal Pharmaceuticals, Inc.
7.42
+1.37%
 
RDY Dr. Reddy's Laboratories Limited
14.74
+0.14%
 
EBS Emergent BioSolutions Inc.
6.30
-0.32%
 
DERM Journey Medical Corporation
7.81
-3.10%
 
ASRT Assertio Holdings, Inc.
0.6566
-1.16%
 
TAK Takeda Pharmaceutical Company Limited
15.08
+0.33%